Von Willebrand Factor in Pregnancy (VIP) Study
Public ClinicalTrials.gov record NCT04146376. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Von Willebrand Factor in Pregnancy (VIP) Study: A Multicenter Study of Wilate Use in Von Willebrand Disease for Childbirth
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding. This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum period, followed by levels of 50-100% for 5-10 days after delivery, depending upon the route of delivery. The primary objective is to document the rate of primary postpartum hemorrhage (PPH). The secondary objective is to document further effectiveness outcomes and safety.
Study identification
- NCT ID
- NCT04146376
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Interventions
- Use of a postpartum diary and additional blood draws. Other
- VWF replacement therapy with Wilate Drug
- Tranexamic acid Drug
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 11, 2019
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Dec 17, 2025
2019 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado | Aurora | Colorado | 80045 | Recruiting |
| Yale University | New Haven | Connecticut | 06510 | Recruiting |
| University of Miami | Miami | Florida | 33136 | Recruiting |
| Emory University | Atlanta | Georgia | 30308 | Recruiting |
| Bleeding & Clotting Disorders Institute | Peoria | Illinois | 61615 | Recruiting |
| Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders | New Orleans | Louisiana | 70112 | Recruiting |
| Oregon Health & Science University | Portland | Oregon | 97239 | Withdrawn |
| The Pennsylvania State University | Hershey | Pennsylvania | 17033 | Recruiting |
| Vanderbilt University | Nashville | Tennessee | 27232 | Recruiting |
| University of Utah | Salt Lake City | Utah | 84108 | Recruiting |
| Washington Center for Bleeding Disorders | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04146376, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04146376 live on ClinicalTrials.gov.